AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Chairman’s report (verbal update)
5. Minutes of previous meeting
   - Matters arising
6. **Appraisal 2:**
   Aliskiren (Rasilez®) for the treatment of essential hypertension
   **This appraisal is postponed**
7. **Appraisal 3:**
   Eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria
8. **Appraisal 4:**
   Maraviroc (Celsentri®) for the treatment-experienced adults infected only with CCR5-tropic HIV-1
9. **Appraisal 5:**
   Anidulafungin (Ecalta®) for the treatment of invasive candidiasis in adult non-neutropenic patients
10. **Appraisal 6:**
    Nelarabine (Atriance®) for the treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma
11. **Appraisal 1 (in light of independent review)**
    Ambrisentan (Volibris®) for the treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional Class II and III, to improve exercise capacity, decrease the symptoms of PAH and delay clinical worsening
   
   **Enclosure**

   **Appendices**

12. **Update on AWPAG**
    Terminology for shared care, near patient testing and enhanced services - subcutaneous methotrexate
13. Date of next meeting: Wednesday, 24th June 2009